September 2020 • Special Supplement
repertoiremag.com
Flu/COVID-19 Special Supplement
SEPTEMBER 2020 • SPECIAL SUPPLEMENT
CONTENTS 4 Which flu test is right for your customer? 6 Gain insights into COVID-19 testing options 8 BD Veritor™ System for COVID-19 (SARS-CoV-2) testing now available 10 Supporting our healthcare workers during a scarcity of disinfectants
2
September 2020
•
Special Supplement
•
www.repertoiremag.com
FLU/COVID-19
Which flu test is right for your customer? Each year, despite forewarnings, the United States and European countries are sometimes caught off guard with
a “Perfect Storm” of challenges for the influenza season. Physician offices should be stocking up on flu tests and other supplies in preparation for this year’s flu season. What do they need to know before they choose a flu test?
ʯ Sample type: Does the test need to allow for multiple sample types (nasal, nasopharyngeal, aspirate/wash, and/or viral transport media (VTM))? ʯ Connectivity: Does the device need to be able to transmit the results electronically? ʯ Cost of the test ʯ The time to result ʯ Does the test require confirmation testing for negative results?
What’s Out There?
What clinicians and distributors can do to prepare First, conducting a business assessment of what the clinicians experienced last year and looking at historical data can help dictate a plan to ensure they procure enough product. Second, weigh the pros and cons of the tests they are currently using and tests they might be considering. Clinicians should consider the following: ʯ Performance: Is test sensitivity and specificity the most critical? ʯ Volume: How many tests does your facility perform during an average flu season? ʯ Ease of Use: How simple is the test to perform? ʯ CLIA Complexity: Does the facility require Waived Complexity or Moderate Complexity Tests? ʯ Results reporting: Is it important for your facility to have an instrument-based result or visual read result, or is either one acceptable?
There are several types of flu tests available on the market. ʯ Rapid molecular tests detect the genetic material of the virus and typically produce results in 30 minutes or less. These are considered to be more accurate than other methods. ʯ Rapid lateral flow immunochemical tests can be either read visually or by an instrument and are intended to detect the presence (or absence) of a target antigen in 15 minutes or less. Depending on what characteristics are important to the clinician will help determine what type of test is a good fit for the facility. The manufacturer and distribution representative would be able to help guide the clinician to a product that is just right for them.
The 5 “Ps” In the end, it comes down to the 5 “Ps” – Proper Preparation Prevents Poor Performance! Physicians shouldn’t be afraid to keep stock of flu tests all year round. Understand new options – with the fear of changing strains, new technologies are more important than ever. Just remember, you have choices!
Learn more about options at www.flutesting.com. Article contribution by Sekisui Diagnostics.
4
September 2020
•
Special Supplement
•
www.repertoiremag.com
Stronger Clinical Performance Takes Lateral Flow Testing To The Next Level
Providing superior rapid results at the point-of-care. Fast, easy, cost effective so you can test and treat in one visit. High Performance Equivalent to or exceeding the performance of reader devices, without the need for an instrument
SENSITIVITY
SPECIFICITY
Results in 10 minutes OSOM® Custom Care Exceptional Support/Training by licensed medical technologists and experienced healthcare professionals Made in the USA Award-winning supply chain capabilities For more information please call us at 800-332-1042 or visit us online at www.osomtests.com © 2020 Sekisui Diagnostics, LLC. All rights reserved. OSOM® is a registered trademark of Sekisui Diagnostics, LLC. Because every result matters™ is a trademark of Sekisui Diagnostics, LLC.
FLU/COVID-19
Gain insights into COVID-19 testing options
Trying to make sense of the continually evolving
information on coronavirus testing? Check out our quick 7-minute educational video where Roche’s Medical and Scientific Affairs partner, Dr. John Osiecki, breaks down the different types of COVID-19 tests that are available today. In this informative discussion, you’ll gain a better understanding of: ʯ Technologies used in current diagnostic tools for COVID-19 ʯ Attributes of the test types and the information they provide ʯ The role of different testing solutions in patient management 6
September 2020
•
Special Supplement
•
www.repertoiremag.com
Explore today’s COVID-19 testing solutions and what they mean for your patients. Watch the Video: https://link.videoplatform.limelight. com/media/?mediaId=400b54795dda4ea28729e0db54 8cce58&width=1024&height=576&playerForm=Player &embedMode=html&htmlPlayerFilename=limelightjsplayer.js. Stay up-to-date on Roche’s response to the coronavirus disease 2019 (COVID-19) outbreak LEARN MORE: https://diagnostics.roche.com/us/en/ landing-pages/roche-covid-19-updates.html.
PERHAPS IT’S THE FLU. CLIA-waived, lab-quality Influenza A/B, RSV and Strep A testing at the point of care. No confirmation necessary for negative test results. The cobas® Liat® PCR System is the only real-time PCR system with three CLIA-waived tests that can be performed in 20 minutes or less. It’s specifically designed for the point-of-care use— so in just three easy steps, clinicians can get accurate, actionable results that help them make the right treatment faster.
Go to cobasliat.roche.com for more information.
COBAS and LIAT are trademarks of Roche Diagnostics. ©2020 Roche. MC-US-06083-0220
FLU/COVID-19
BD Veritor™ System for COVID-19 (SARS-CoV-2) testing now available Designed to meet the evolving and critical needs of point-of-care (POC) testing, the BD Veritor™ Plus system
enables you to streamline the testing experience. Be ready for flu season by testing with CLIA-waived Flu A+B, Group A Strep, and respiratory syncytial virus (RSV) assays along with the SARS-CoV-2 assay,* which is FDA authorized for emergency use in the current public health emergency.
The BD Veritor™ Plus system is an easy-to-use portable testing device that provides fast, reliable, and traceable results in acute as well as nonacute settings for Flu A+B, Group A Strep, RSV assays, along with a SARSCoV-2 assay under FDA emergency use authorization.
Understanding the needs of modern POC testing, results are fast – delivered in 15 minutes for SARSCoV-2, <11 minutes for flu and RSV, and <6 minutes for Group A Strep. Contributing to the reliability, the system enhances sensitivity by using a proprietary and stable detection particle technology, which helps improve test performance. Simple and easy to operate, Flu A+B, Group A Strep, and RSV assays have all received CLIA-waived status to allow novice and nonlab personnel to test confidently. BD Veritor™ Plus system users also have access to the BD eLearning Platform, which provides quick, efficient, and customized training for the BD Veritor™ Plus system. Results are designed to be traceable with the use of an optional BD Veritor™ InfoScan module, which allows users to reliably customize quality control and result documentation (user ID, specimen ID, and test kit/lot). Traceable results may reduce risk of potential reporting errors by minimizing manual transcription, leveraging data storage/download and printing capabilities via USB. The BD Veritor™ Plus system is powered by BD Synapsys™ Informatics, helping to streamline the testing experience with an integrated workflow and on-demand insights to keep up with the new demands of POC testing. To learn more, visit https://go.bd.com/Veritor-Repertoire.
*• This test has not been FDA cleared or approved; • This test has been authorized by FDA under an EUA for use by authorized laboratories; • This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, • This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner
8
September 2020
•
Special Supplement
•
www.repertoiremag.com
FDA-GRANTED EMERGENCY USE AUTHORIZATION FOR SARS-CoV-2 ASSAY* Powered by BD Synapsys™ Informatics
Harness the Power of Simplicity
*The SARS-CoV-2 assay:
The simple, fast, and reliable BD Veritor™ Plus system,
• Has not been FDA cleared or approved
powered by BD Synapsys™ Informatics, streamlines
• Has been authorized by FDA under an EUA for use by authorized laboratories
point-of-care testing for CLIA-waived Flu A+B, Group A Strep, and RSV assays, plus a SARS-CoV-2 assay* with FDA emergency use authorization. To learn more visit https://go.bd.com/Veritor-Repertoire
BD, the BD Logo, BD Veritor, and BD Synapsys are trademarks of Becton, Dickinson and Company or its affiliates. © 2020 BD. All rights reserved. 551-US-0720 July 2020
• Has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens • Is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner
FLU/COVID-19
Supporting our healthcare workers during a scarcity of disinfectants Surface disinfection wipes are scarce in the face of a pandemic. The global supply chain of surface disinfectants
has been heavily impacted by the pandemic, and limitations on ordering have happened as a result of raw material and extensive back orders throughout the industry.
Understanding the impact To continually supply dealers, we have substantially increased our surface disinfection liquids as it contains the same active ingredients as our wipes. It is not currently limited to the same constraints as wipes, but we still see a heightened demand of course. For end users to make this temporary conversion, a non-cotton-based paper towel can be used in combination with the liquid, following the proper wipe procedure and contact time. An alternative to using wipes is CaviCide, as it is the same solution used to impregnate CaviWipes.
A: General Cleaning Order Considerations: Top to Bottom, Clean to Dirty, Clockwise or Counter-Clockwise Through the Room. Ensure the staff is on consistent with the guidance provided. ppropriate products to use during COVID-19. A Are the disinfectants you are using on EPA List N? A: All products on this list meet EPA’s criteria for use against SARS-CoV-2, the virus that causes COVID19. Both CaviCide and CaviWipes are on EPA’s List N. uggestions when wipes cannot be found. S How about switching to a liquid disinfectant in the meantime? A: An option can be finding a disinfecting liquid that compliments the wipe. For example, CaviCide liquid surface disinfection spray is the same solution that impregnates CaviWipes. Be prepared to have an answer to this question if you recommend a liquid disinfectant. Combatting Aerosols. I am concerned about the spray aerosols. How do I mitigate this?
Finding alternative solutions for our customers In the face of a pandemic and allocations across key infection prevention categories in the industry, we must find a way to support our customers by finding alternative solutions to meet their needs. Distributor reps can ask key questions like: Appropriate product usage. Do you know how to disinfect properly and efficiently? 10
September 2020
•
Special Supplement
•
www.repertoiremag.com
ssess dispensing options. CaviCide 24 oz has 3 disA pensing options with its trigger sprayer – spray, stream and off. The stream option aerosolization and is encouraged if you are concerned about aerosols in your facility. Be a resource to your customers during this time. To learn more about Metrex, visit Metrex.com, or get in touch with a MedPro representative.
KILLS NOVEL CORONAVIRUS
(COVID-19)
*
ON EPA LIST N
A Portfolio of Products Built for a Pandemic Surface disinfection wipes are scarce in the face of a pandemic. However, no wipes, no problem. CaviCide™ and CaviCide1™ compliment CaviWipes™ and CaviWipes1™ respectively, as the disinfectant is the solution that impregnates the wipes. All our surface disinfectants are on EPA’s List N.
*List N: Disinfectants for Use Against SARS-CoV-2. https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2. Accessed 7.27.2020. To kill SARS-CoV-2 (COVID-19), please follow the disinfection instructions for each product in accordance with List N.
MKT-20-0656 • ©2020 Metrex Research
Trusted Since 1985.